Rottendorf Pharmaceuticals, the US-based subsidiary of German company Rottendorf Pharma, signed in the last quarter three formulation development projects and two commercial transfer projects with multiple top 5 pharmaceutical and biopharmaceutical companies.

"The new projects signed in the last quarter reflect the industry's positive response to our business model and our commitment to Total Process Ownership (TPO)," said Rottendorf Pharmaceuticals CEO Gordon Haines. "TPO relies on open communication and exchange of ideas with our pharma partners and draws on 85 years of formulation development and manufacturing experience to recommend process optimizations to ultimately produce a better end product."

"We are owned by a charitable foundation, which allows us to focus more on long-term success of our business and the goals of our customers, rather than needing to satisfy shareholders on a quarter-by-quarter basis," Haines added.

Recently Rottendorf won five separate 2015 CMO Leadership Awards presented by Life Science Connect. The awards are based on survey results of more than 65,000 questionnaires sent to a broad range of both pharma and biotech companies.